Company intelligence / Profile preview

Adimend

Lebanon, New Hampshire, United Statesipoi.gov.ie ↗

Ownership: Private
Employees: ~162
Development stage: Other

Overview

Adimab has enabled over 70 clinical-stage antibody programs through its partners, leveraging its proprietary yeast-based discovery technology. It does not develop internal therapeutics but provides leads and optimization services to pharma/biotech clients.

Modalities: Fully human monoclonal antibodies (IgGs)Bispecific antibodies / multispecificsSingle domain antibodies (HCAbs)CARs (Chimeric Antigen Receptors)
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Adimend.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adimend.

Explore the full profile